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Abstract
Periodontal bone loss results from bacterial infection and the associated host response. The ligand for
the receptor activator of NF-κB (RANKL) induces the differentiation of osteoclasts, resulting in
periodontal bone loss. The role of osteocytes in periodontal bone loss was investigated in this study.
Transgenic mice expressing RANKL under the control of dentin matrix protein 1 (DMP1) were infected
with Porphyromonas gingivalis- Fusobacterium nucleatum bacteria (Pg-Fn) to induce periodontitis, and
type 1 diabetes was induced in groups of mice. Control (DMP1Cre−.RANKLf/f) mice with periodontal
infection showed increases in bone loss, osteoclast counts, eroded bone surfaces, and RANKL
expression compared to experimental (DMP1-Cre+.RANKLf/f) mice. RANKL deletion from osteocytes
resulted in less periodontal bone loss. Diabetes enhanced periodontal bone loss in the control mice. The
diabetic control (DMP1Cre−.RANKLf/f) mice had more bone loss than the non-diabetic control (DMP1Cre−.RANKLf/f) mice. In the experimental (DMP1-Cre+.RANKLf/f) mice, diabetes had no influence. This
study demonstrated, for the first time, the essential role of osteocytes in periodontal bone loss.
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ABSTRACT
Periodontal bone loss results from bacterial infection and the associated host
response. The ligand for the receptor activator of NF-κB (RANKL) induces the
differentiation of osteoclasts, resulting in periodontal bone loss. The role of
osteocytes in periodontal bone loss was investigated in this study. Transgenic mice
expressing RANKL under the control of dentin matrix protein 1 (DMP1) were
infected with Porphyromonas gingivalis- Fusobacterium nucleatum bacteria (PgFn) to induce periodontitis, and type 1 diabetes was induced in groups of mice.
Control (DMP1 Cre−.RANKLf/f) mice with periodontal infection showed
increases in bone loss, osteoclast counts, eroded bone surfaces, and RANKL
expression compared to experimental (DMP1-Cre+.RANKLf/f) mice. RANKL
deletion from osteocytes resulted in less periodontal bone loss. Diabetes enhanced
periodontal bone loss in the control mice. The diabetic control
(DMP1 Cre−.RANKLf/f) mice had more bone loss than the non-diabetic control
(DMP1 Cre−.RANKLf/f) mice. In the experimental (DMP1-Cre+.RANKLf/f) mice,
diabetes had no influence. This study demonstrated, for the first time, the essential
role of osteocytes in periodontal bone loss.
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Literature review
Periodontal disease is a group of disorders that affect the periodontium. When inflammation is
confined to gingiva without attachment loss, it is called gingivitis, and when it progresses to
connective tissue and bone, resulting in attachment loss that manifests as pocket formation
and/or gingival recession, it is referred to as periodontitis. Periodontitis is a biofilm-induced
infectious disease that affects the periodontium; about 46% of US adults have periodontitis (Eke
et al. 2015).
Dental plaque plays an essential role in the initiation of periodontal disease. However, it is the
host response to this infection that propagates destruction in the periodontium. A biofilm is a
multi-species community of microorganisms that adhere to each other and a surface and are
embedded in an extracellular matrix (a complex polymeric substance that protects the
microorganisms from environmental stresses). Bacteria living in a biofilm differ in physiology
from free-living bacteria and are more difficult to eradicate with antibiotics. Dental plaque is the
prototypical example of a biofilm (Glossary of Periodontal Terms, AAP, 2012). Up to 700
bacterial species are able to colonize the mouth, and any individual may typically harbor 200300 species (Griffen et al. 2011).
Many bacteria species are involved in subgingival pockets and associated with periodontal
diseases. They include P. gingivalis, T. forsythia, T. denticola, F. nucleatum, P. intermedia, and
Aggregatibacter actinomycetemcomitans (Dzink et al. 1988, Lisgarten Max A. 1994, Socransky
et al. 1998). As periodontal disease progresses, there is a shift from gram-positive microbiota to
gram-negative anaerobic bacteria. These bacteria can produce factors that directly or indirectly
cause the destruction of the periodontium, namely lipopolysaccharides (endotoxins), collagenase,
immunoglobulin proteases,	
  fibrinolysins, and hemolysins (Holt SC and Bramanti TE. 1991).
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As bacteria invade the sulcus, an initial gingivitis lesion develops. An early lesion is next,
followed by an established lesion. The subsequent stage is that of the advanced lesion (Page and
Scheroder 1976). The advanced lesion marks the transition from gingivitis to periodontitis.
IL-1 and TNF from keratinocytes, endothelial cells, and other cells are capable to induce the
production of IL-8, which is a major cytokine involved in the recruitment of neutrophils to the
site of inflammation (Oppenheim et al. 1991). The vascular permeability increases and
complement activation occurs, resulting in the increased recruitment of neutrophils and
monocytes. Macrophages produce PE2 (Offenbacher et al. 1993), which has the effect of bone
resorption and produces other inflammatory mediators, including IL-lβ, 6, 10, and 12, tumor
necrosis factor α (TNFα), matrix metalloproteinases (MMPs), interferon γ (INFγ), and a series
of chemotactic substances (monocyte chemoattractant protein (MCP), macrophage inflammatory
protein (MIP), and RANTES (regulated on activation, normal T-cell expressed and secreted))
(Korman et al. 1997, Page et al. 1997). As the inflammation progresses to deeper connective
tissue, fibroblasts play a major role in periodontal breakdown by producing pro-inflammatory
mediators such as PE2 and MMPs.
Activated T cells produce a large number of inflammatory cytokines that induce the further
destruction of the periodontium and facilitate the differentiation of B cells and the production of
antibodies. Th1 is a type of CD4+ T cell that produces pro-inflammatory cytokines such as INF γ
(Vitetta et al. 1987, Mosmann and Coffman. 1989). There is evidence that Th17 cells are present
in chronic inflammation in human periodontal disease and that IL-17 expression occurs in the
alveolar bones of patients with chronic periodontitis (Cardoso et al. 2009).
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Periodontal bone resorption due to osteoclastic activity is related to the proximity of the
inflammatory infiltrate (Rowe and Bradley 1981). The receptor activator of nuclear factor
kappa-B (RANK) and its ligand (RANKL) was recognized as a member of the family of tumor
necrosis factor (TNF) receptors and ligands (Anderson et al. 1997, Wong et al. 1997). RANKL is
a type II transmembrane protein of 316 amino acids with a predicted cytoplasmic domain of 48
amino acids and an extracellular domain of 247 amino acids (Anderson et al. 1997).
Osteoprotegerin (OPG) is another member of the TNF receptor family (Simonet et al. 1997); it is
a decoy RANKL receptor that prevents RANKL from binding to the receptor activator of nuclear
factor kappa-B (RANK) and results in the inhibition of bone resorption. RANKL, RANK, and
OPG are three key molecules that regulate osteoclast recruitment and function (Suda et al. 1999).
Osteoclasts are multinucleated cells that originate from hematopoietic precursors and are
responsible for bone resorption (Scott B.L. 1967, Marks S.C. 1983).
RANKL was identified as a major factor for oesteoclastogenesis (Kong et al. 1999): RANKLdeficient mice showed severe osteopetrosis with no osteoclast formation (Kim et al. 2000). TNFα
and β, and IL-1α and β are involved in the stimulation of osteoclastic bone resorption
(Pfeilschifter et al. 1989, Balga et al. 2006). IL-6 plays a role in the stimulation of osteoclast
formation by inducing the release of IL-1β (Lowik et al. 1989, Kurihara et al. 1990). Another
osteoclastogenic cytokine is IL-11 (Girasole et al. 1994). RANKL expression has been identified
in various tissues, including T cells, dendritic cells (Wong et al. 1997), osteoblasts (V.
Kartsogiannis et al. 1999), osteocytes (Tanaka et al. 1995), and fibroblasts (Kanzaki et al. 2001).
Several risk factors that affect periodontal diseases have been identified. One of the most
important ones is diabetes mellitus (AAP academy report 1999, Mealy and Oates 2006). The
term “diabetes mellitus” describes a metabolic disorder of multiple etiologies that is
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characterized by chronic hyperglycemia with disturbances of carbohydrate, fat, and protein
metabolism and results from defects in insulin secretion, insulin action, or both (Zimmet and
Alberti 1998). Type 1 diabetes (previously known as insulin-dependent, juvenile, or childhoodonset diabetes) is characterized by deficient insulin production and requires the daily
administration of insulin. The cause of type 1 diabetes is not known, and it is not preventable
with current knowledge. Symptoms include the excessive excretion of urine (polyuria), excessive
thirst (polydipsia), constant hunger, weight loss, changes in vision, and fatigue. These symptoms
may occur suddenly. Type 2 diabetes results from the body’s lack of response to insulin
combined with inadequate production of insulin to compensate for the insulin resistance. Type 2
diabetes accounts for 90% of the cases of diabetes around the world (Zimmet and Alberti 1998)
and is largely the result of excess body weight and physical inactivity. The associated symptoms
may be similar to those of type 1 diabetes, but they are often less marked. As a result, the disease
may be diagnosed several years after onset, once complications have already arisen. Until
recently, this type of diabetes was evident in adults, but it now also occurs in children (WHO
Diabetes Fact Sheet, 2015). According to recent statistics, 9.3% of (29.1 million) Americans
have diabetes, and 25.9% of the population aged 65 years or more has diabetes (CDC. National
Diabetes Statistics Report, 2014). Periodontitis is considered to be the sixth complication of
diabetes mellitus; diabetes mellitus is associated with increased periodontal attachment and bone
loss (Löe H. 1993). As early as 1862, there were reports linking diabetes mellitus to severe
periodontal destruction; diabetic patients with periodontal diseases experienced more gingival
inflammation and attachment loss than non-diabetic periodontitis patients (Cohen et al. 1970).
Diabetes is associated with elevated levels of inflammatory mediators. Advanced glycation end
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products (AGEs) are associated with increased oxidative stresses and upregulate inflammatory
mediators such as IL-1β, TNFα, and IL-6 (Preshaw et al. 2012).
Diabetes enhances monocytic TNFα activity in diabetic patients with periodontitis 4.6 times
(Salvi et al. 1997). Other studies show elevated levels of pro-inflammatory cytokines, including
IL-1β, TNFα and PGE2, in diabetic patients with periodontal disease (Salvi et al. 1997). Diabetes
associated with an altered inflammatory response to bacteria impacts periodontitis, wound
healing, and apoptosis (Graves et al. 2006).
In normal bone remodeling, bone resorption and bone formation are coupled. However, in
periodontitis, this coupling is impaired (Baylink and Liu CC. 1979). In diabetes, cytokines such
as IL-1β and TNFα can up-regulate RANKL expression in periodontal cells and increase
osteoclast formation (Pacios et al. 2012). Due to persistent bacterial inflammation, diabetes
results in the aggravation of the condition through enhanced bone loss and diminished bone
formation (Liu et al. 2006).
Since it is unethical to investigate disease processes in humans, animal models have been
introduced, allowing the investigation of disease processes and cause-effect relationships.
Animal models, including those involving mice (Baer and Newton. 1960), rats (Rovin et al.
1966), squirrel monkeys (Kennedy and Polson 1973), and beagle dogs (Saxes et al. 1967) have
been described to investigate periodontitis. Different animal models for studying periodontitis
have been established. They include the rat ligature model, the rat A. actinomycetemcomitans
infection model, the oral gavage model, the lipopolysaccharide injection model, the calvarial
model, and the rat-mandibular critical size defect model (Graves et al. 2008, Graves et al. 2012).
Polak et al. (2009) showed that oral inoculation with Porphyromonas gingivalis-Fusobacterium
nucleatum bacteria (Pg-Fn) was an effective model for studying periodontitis.
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Mouse models are considered to be among the best animal models of disease: Mice and humans
share 95-99% of their DNA (Gregory et al. 2002, Waterston et al. 2002). The ability to knock out
a specific mouse gene induced a huge advance in understanding the nature of the disease and
offered promising insights into possible treatments. More than 4,000 out of ~35,000 mouse genes
have been knocked out, and more than 500 mouse models of human disease have been created
(Goldstein J. 2001, Austin et al. 2004).
The expression of RANKL in B and T lymphocytes in periodontal tissues was investigated.
RANKL from B and T lymphocytes reported to be higher in patients with chronic periodontitis
than in patients with healthy periodontium (Kawai et al. 2006). RANKL mRNA was higher in
advanced periodontitis, and the level of OPG mRNA associated with both advanced and
moderate periodontitis was lower than that in the healthy group. Moreover, RANKL mRNA was
expressed in inflammatory cells, mainly lymphocytes and macrophages. In addition, the
proliferating epithelium in the vicinity of inflammatory cells expressed high levels of RANKL
mRNA (Liu et al. 2003).
IL-1a stimulated both the upregulation of RANKL expression and the downregulation of OPG
expression via PGE2 production, depending on ERK activation of human periodontal ligament
fibroblasts (Fukushima et al. 2005). By contrast, another study showed that PDL fibroblasts
played a protective role in inflammation and LPS stimulated the expression of OPG rather than
that of RANKL in periodontal ligament fibroblasts through the induction of IL-1β and TNFα
(Wada et al. 2004). Human PDL fibroblasts from patients with chronic periodontitis expressed a
RANKL level 2.5 times higher than that of healthy gingival fibroblasts and higher levels of IL-6
and TNFα (Matarese et al. 2015).
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Osteoblast lineage cells express RANKL for differentiation and the activation of osteoclasts
(Lacey et al. 1998, Hofbauer et al. 2000). Mice with RANKL deficiency in osteoblast lineage
were protected from bone loss induced by ovariectomy and from joint destruction associated
with arthritis, whereas the loss of RANKL in T cells did not confer such protection (Fumoto et
al. 2014). Another study demonstrated the important role of osteoblast lineage cells in
inflammation-induced periodontal bone loss (Pacios et al. 2015). P. gingivalis-infected mouse
osteoblastic cells induced RANKL expression in osteoblasts through activator protein1 (AP-1)
signaling pathways (Okahashi et al. 2004).
For many years, osteocytes were thought to be inactive cells that resided inside lacunae. Recent
studies have revealed these cells’ major role in controlling bone hemostasis (Dallas et al. 2013,
Al-Dujaili et al. 2011). RANKL expression by osteocytes was first identified in vitro in chick
cells (Tanaka et al. 1995). Later, MLO-Y4 osteocyte-like cells (from mice) expressed RANKL
on their surfaces (Zhao et al. 2002). There is recent evidence of the regulation of bone
remodeling by osteocytes through RANKL expression; the deletion of RANKL from osteocytes
results in an increase in bone mass (Xiong et al. 2011, Xiong et al. 2015). RANKL expression in
osteocytes is essential for osteoclast formation and for controlling bone remodeling (O’Brien and
Xiong 2012, Nakashima et al. 2011) as well as controlling bone loss in unloaded conditions
(Xiong et al. 2011, Tatsumi et al. 2007).
The role of osteocytes in periodontitis-associated bone loss has not been fully studied. RANKL
expression by those cells has been established, but the magnitude of the effect of those cell type
in periodontal bone loss is still to be investigated.
Dentin matrix acidic phosphoprotein 1 (DMP1) is a major constituent of the extracellular matrix
of bone and dentin; it was first isolated from dentin (Georg et al. 1993)	
  then	
  from	
  enamel, bone,
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and cementum (D'Souza et al. 1997, MacDougall et al. 1998). Recent studies demonstrate that
osteocytes express high levels of DMP1 (Toyosawa et al. 2001, Feng et al. 2002, Lu et al. 2007,
Canalis et al. 2013). Transgenic mice expressing the diphtheria toxin receptor under the control
of dentin matrix protein 1 (DMP1) promoter serve as a mouse model for the study of osteocytes
(Komori T. 2014).
Cre (cyclization recombination) is a site-specific recombinase that allows for deletions,
insertions, or modification at specific sites in the DNA of cells utilizing the Cre/loxP system
(where “loxP” refers to the locus of crossing [x-ing]-over of bacteriophage P1). The Cre/loxP
system functions by delivering Cre to specific cells or tissues using a particular promoter. The
Cre recombinase excises the essential exon of the gene of interest, which is floxed (sandwiched
between two loxP sites), thus generating a null allele in all cells where Cre is active.
Cre activity under the control of the 9.6-kb DMP1 promoter gene was established (Lu et al.
2007). Using Cre recombinase, it is possible to delete the floxed RANKL genes (encoded by the
Tnfsf11 gene) in cells expressing the DMP1 gene in transgenic mice (Nakashima et al. 2011).
To confirm the selective deletion of RANKL in osteocytes, a reporter mouse R26R line that
expressed ROSA26 reporter genes was crossed with (DMP1 Cre.RANKLf/f) transgenic mice.
By detecting b-galactosidase activity with either X-gal staining or immunofluorescence staining
that targets b-galactosidase in the tissues, we can examine the effectiveness of Cre activation and
identify the tissue-specific distribution of Cre recombinase with a specific promoter (Soriano P.
1999).
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Introduction
Periodontitis is an inflammatory disease that results in clinical attachment loss, alveolar bone
loss, and periodontal pocketing. It is initiated by a bacterial biofilm and progresses due to a host
response that leads to soft and hard tissue destruction (Graves	
   and	
   Cochran 2003). Up to 700
bacterial species can colonize the mouth; any individual may typically harbor 200-300 such
species (Griffen et al. 2011). Many bacterial species are involved in subgingival pockets and
associated periodontal diseases. They include P. gingivalis, T. forsythia, T. denticola, F.
nucleatum, P. intermedia, and Aggregatibacter actinomycetemcomitans (Dzink et al. 1988,
Lisgarten Max A. 1994, Socransky et al. 1998).
Tissue destruction is mediated by the production of cytokines by many types of cells. Examples
of these cytokines are IL-1β, TNFα (Graves 2008), and the ligand for the receptor activator of
NF-κB (RANKL), which induce the differentiation of osteoclasts (Yamashita et al. 2007).
RANKL-deficient mice showed severe osteopetrosis with no osteoclast formation (Kim et al.
2000).
RANKL from lymphocytes was considered the primary cause of osteoclast-induced periodontal
bone loss (Kawai et al. 2006). However, a recent study (Pacios, S. et al. 2015) demonstrated the
important role of osteoblast-lineage cells in inflammation-induced periodontal bone loss.
RANKL expressed in osteocytes is essential for osteoclast formation and controlling bone
remodeling (O’Brien and Xiong 2012, Nakashima et al. 2011) as well as controlling bone loss in
unloaded conditions (Xiong et al. 2011, Tatsumi et al. 2007).
Dentin matrix acidic phosphoprotein 1(DMP1) is a major constituent of the extracelluar matrix
of bone and dentin. It was first isolated from dentin (Georg et al. 1993)	
  then	
  from	
  enamel, bone,
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and cementum (D'Souza et al. 1997, MacDougall et al. 1998), Recent studies demonstrate that
DMP1 is expressed at high levels in osteocytes (Toyosawa et al. 2001, Feng et al. 2002, Lu et al.
2007, Canalis et al. 2013).
Oral inoculation with Pg-Fn bacteria is an effective model for studying periodontitis (Graves et
al. 2008, Graves et al. 2012, Polak et al. 2009). Transgenic mice expressing the diphtheria toxin
receptor under the control of dentin matrix protein 1 (DMP1) promoter serve as a mouse model
for studying osteocytes (Tatsumi et al. 2007, Komori T. 2014).
Several risk factors that affect periodontal diseases have been identified; one of the most
important factors is diabetes mellitus (AAP academy report 1999, Mealy and Oates 2006).
According to recent statistics, 9.3% of (29.1 million) of Americans have diabetes, and 25.9% of
the population aged 65 years or more have diabetes (CDC. National Diabetes Statistics Report,
2014). Periodontitis is considered to be the sixth complication of diabetes mellitus; diabetes
mellitus is associated with increased periodontal attachment and bone loss (Löe H. 1993). As
early as 1862, there were reports linking diabetes mellitus to severe periodontal destruction;
diabetic patients with periodontal diseases had more gingival inflammation and attachment loss
than non-diabetic periodontitis patients (Cohen et al. 1970). Diabetes is associated with elevated
levels of inflammatory mediators. Moreover, advanced glycation end products (AGEs) are
associated with increased oxidative stress and upregulate inflammatory mediators such as IL-1β,
TNFα, and IL-6 (Preshaw et al. 2012).
Diabetes enhances monocytic TNFα activity in diabetic patients with periodontitis 4.6 times
(Salvi et al. 1997). Other studies show elevated levels of pro-inflammatory cytokines, including
IL- 1β, TNFα, and PGE2, in diabetic patients with periodontal disease (Salvi et al. 1997).
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Diabetes associated with altered inflammatory responses to bacteria has an impact on
periodontitis, wound healing, and apoptosis (Graves et al. 2006).
In normal bone remodeling, bone resorption and bone formation are coupled. However, in
periodontitis, this coupling is impaired (Baylink and Liu CC. 1979). In diabetes, cytokines such
as IL-1β and TNFα can up-regulate RANKL expression in periodontal cells and increase
osteoclast formation (Pacios et al. 2012). Due to persistent bacterial inflammation, diabetes
results in the aggravation of the condition through enhanced bone loss and diminished bone
formation (Graves et al. 2006).
Cre (cyclization recombination) is a site-specific recombinase that allows for deletions,
insertions, or modification at specific sites in the DNA of the cells utilizing the Cre/loxP system
(where “loxP” is the locus of crossing [x-ing]-over of bacteriophage P1). The Cre/loxP system
works by delivering Cre to specific cells or tissues using a particular promoter. The Cre
recombinase excises the essential exon of the gene of interest, which is floxed (sandwiched
between) two loxP sites, thus generating a null allele in all cells where Cre is active.
Cre activity under control of the 9.6-kb Dmp1 promoter gene was established (Lu et al. 2007).
Using Cre recombinase, it is possible to delete the floxed RANKL genes (encoded by the
Tnfsf11 gene) in cells expressing the DMP1 gene in transgenic mice (Nakashima et al. 2011).
To confirm the selective deletion of RANKL in osteocytes, a reporter mouse R26R line that
expressed ROSA26 reporter genes was crossed with (DMP1 Cre.RANKLf/f) transgenic mice.
By detecting b-galactosidase activity with either X-gal staining or immunofluorescence staining
that targeted b-galactosidase in the tissues, it was possible to examine the effectiveness of Cre
activation and identify the tissue-specific distribution of Cre recombinase with a specific
promoter (Soriano P. 1999).
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Since no published studies have evaluated the role of osteocytes in periodontitis, the aim of this
study is to investigate the role of RANKL from osteocytes in periodontitis-induced bone loss and
to determine whether diabetes has an influence on it.
The first null hypothesis (H0) follows: RANKL deletion from osteocytes will have no effect on
periodontal bone loss. Its alternative hypothesis (H1) follows: RANKL deletion from osteocytes
will result in less periodontal bone loss.
The second null hypothesis (H0) follows: RANKL deletion from osteocytes in diabetic subjects
will have no effect on periodontal bone loss. Its alternative hypothesis (H1) follows: RANKL
deletion from osteocytes in diabetic subjects will result in less periodontal bone loss.
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Materials and method
All methods were carried out in accordance with the approved guidelines of the Institutional
Animal Care and Use Committee at the University of Pennsylvania. All mice were housed in the
Levy Animal Facility for Oral Health Research at the University of Pennsylvania School of
Dental Medicine. Later, for the experiment design stage (bacterial inoculation required a
Biosafety Level 2 lab), they were transferred to John Morgan Building’s animal facility at the
University of Pennsylvania’s Perelman School of Medicine.
Transgenic mice (DMP1 Cre.RANKLf/f) were obtained from Dr. Jerry Feng of the Baylor
College of Dentistry in Dallas, Texas. They expressed Cre recombinase under the control of the
Dmp1 promoter in osteocytes as described in the literature (Lu et al. 2007). DMP1-Cre.ROSA26
transgenic mice for monitoring the Cre recombinase expression site were obtained from Jackson
Laboratories (in Bar Harbor, Maine).
All experiments were carried out when the mice were 8-10 weeks old. Two of them were
conducted at the same time. The first experiment compared the effect of RANKL deletion from
osteocytes

on

periodontal

bone

loss

in

the

normoglycemic

experimental

(DMP1 Cre+.RANKLf/f) group to that in the normoglycemic control (DMP1 Cre−.RANKLf/f)
group. The second experiment compared the effect of RANKL deletion from osteocytes on
periodontal bone loss in the hyperglycemic experimental (DMP1 Cre+.RANKLf/f) group to that
in the hyperglycemic control (DMP1 Cre−.RANKLf/f) group.
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Induction of diabetes
The weights of the mice were taken 2 times before the induction of diabetes. When the mice
were approximately 8-10 weeks old, type 1 diabetes was induced in them through the
intraperitoneal injection of streptozotocin (STZ) (50 mg/kg; 5mg/mL in 100 mM sodium citrate
pH 4.5 buffer; Sigma, St. Louis, Missouri) for 5 consecutive days. Control animals were treated
with citrate buffer alone (1.47 gr of sodium citrate to 500 ml distilled water (DW), adjusted pH
4.5). Ten days after the last STZ injection, blood glucose was taken by tail prick to determine
whether hyperglycemia had developed. All glucose measurements were taken in the morning
using blade#11. The weights of the mice were obtained every week after the STZ injection.
The mice were considered to be hyperglycemic when their glucose values exceeded 225 mg/dl.
If the mice were not diabetic, up to 4 more injections was given as follows:
200-220 mg/dl - 1 STZ injection
175-200 mg/dl - 2 STZ injections
150-175 mg/dl - 3 STZ injections
125-150 mg/dl - 4 STZ injections
<125 mg/dl - 5 STZ injections
Diabetic mice are vulnerable to dehydration and weight loss. The mice that lost more than 10%
of weight compared to the control mice were given a dietary supplement (Love Mash™,
Bio.Serv;	
   Flemington, New Jersey). The mice were checked for dehydration; if a mouse was
dehydrated, a subcutaneous injection of 1 mL of 0.9% saline solution (9 g of NaCl to 100 ml
DW) was administered daily. Mice were maintained in the diabetic (hyperglycemic) state for at
least one week before the next step. The final blood glucose measurement was obtained
immediately after euthanasia.
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Antibiotic treatment
A 5-ml preparation of trimethoprim (1.6 mg/ml) and sulfadimethoxine (8 mg/ml) was added to
the drinking water (150 ml of DW) of each cage and changed every other day in the morning for
7 consecutive days. These broad spectrum antibiotics were administered to all mice	
  to reduce the
endogenous oral flora.
Induction of periodontitis
Bacteria preparation and inoculation
For this study, the anaerobic bacteria, Porphyromonas gingivalis (Pg) strain (ATCC 33277) and
Fusobacterium nucleatum (Fn) strain (ATCC 25586), were prepared in an anaerobic chamber
from frozen culture. The bacteria were tested for aerobic contamination. The details of the
bacteria inoculation follow: We inoculated 100 µl (50 µl on each side of the molars) with a
gavage needle in each mouse’s mouth two times, between the mucosal tissue of cheek and the
molar teeth. Overall, P. gingivalis and F. nucleatum (2x10^9 colony forming unit CFU in 200 ul
of 2% methylcelluolose) were given to the mice; the non-infected group was inoculated with the
vehicle alone (100 µl of 2% methylcellulose in sterile PBS). Bacterial inoculation was performed
three times every week over a 2-week period. The mice were monitored for a period of 6 weeks,
and their weights were checked weekly.
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Mouse euthanasia and tissue harvesting
The mice were all euthanized at the same time: during the 6th week. They were decapitated
under 150-200 mg/kg of ketamine and 15-20 mg/kg of xylazine and 1-3 mg/kg of Acepromazine.
Specimens of their tails were obtained for PCR genotyping to confirm the initial genotyping for
RANKL and Cre expression (Figure1).
Tissue harvesting
The specimens were fixed in 5 ml/specimen of 4% paraformaldehyde at 4°C for 24 hours. Then
they were taken for microCT and, subsequently, decalcified in 10% EDTA (Fisher Scientific;
Hampton, New Hampshire) for 4–5 weeks. The specimens were embedded in paraffin and
sectioned in sagittal sections of 4-µm thickness that included the region of the 1st-2nd and 2nd3rd molars, including the teeth, PDL, alveolar bone, and gingiva.
MicroCT analysis
Specimens were scanned using an in vivo MicroCT machine (viva CT40 SCANCO Medical,
Brüttisellen, Switzerland) and analyzed using OssiriX MD imaging software (Pixmeo; Geneva,
Switzerland). The bone area between the first and second molar was measured. Measurement
was performed on the sagittal section of the MicroCT, considering that the root canal of the
distobuccal root of the first molar and the mesiobuccal root of the second molar was visible in
the sagittal section. The first cement-enamel junctions (CEJs) of the first and second molars had
to be identified by increasing the WL contrast to around 8000. A line was drawn from the CEJ of
the first molar to the CEJ of the second molar, another perpendicular line was drawn extending
700 um downwards from each CEJ to the roots, and the last line connected the two vertical lines
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(a box with height of 700 um and oriented on the CEJs of the teeth helped with measurements).
The contrast was decreased to around 3000 for bone area measurement. The area between the
roots, the CEJ, and the height limit line was calculated as the total area. Then the area of the
alveolar bone inside the total area was calculated as the remaining bone area (Figure2a,b).
Afterwards, the percentage of the remaining bone area was calculated using the formula, % of
Remaining Bone Area = (Bone Area/ Total Area)*100.
Histomorphometric analysis
Haematoxylin and eosin staining
Haematoxylin and eosin (H&E) staining were performed on the first slide (the slide that showed
the 1st and 2nd molar crowns, roots, and root canals) of each specimen to ensure consistency.
Bone area measurement was performed using Nikon NIS-elements D image analysis software
(Nikon, Tokyo, Japan) at 20X magnification, as follows: A horizontal line connected the CEJ of
the 1st molar to the 2nd molar, then a vertical line was extended 0.08 mm downwards for the
epithelium and part of the connective tissue. Afterwards, a horizontal line was produced at that
level, and a third vertical 0.32-mm line was made (two verticals, one for each root). The last line
was a horizontal one connecting the two vertical lines. The area between the roots and the two
horizontal lines was measured as the total area, and the bone area was measured the same way
between the two roots and the two horizontal lines: The percentage of the remaining bone area
was calculated using the formula, % Remaining Bone Area = (Bone Area/ Total Area)*100
(Figure3).
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Trap Staining
A trap staining kit (Sigma Aldrich, St. Louis, Missouri), was used for osteoclast staining,
osteoclast counts, and eroded bone measurement that employed Nikon NIS-elements D image
analysis software (Nikon, Tokyo, Japan) at 20X magnification on the second slide of each
specimen to ensure consistency: A horizontal line was made on the top of the interproximal bone
(between the first and second molars). Then a 0.35-mm vertical line was made downwards from
the first horizontal line (one for each root). The last line was a horizontal one connecting those
two vertical lines. The osteoclasts on the distal side of the interproximal bone (mesial to second
molar) were used for the osteoclast count. The number of osteoclasts was then divided by the
bone length (distal bone); resorption lacunae on the distal side were also measured and divided
by the total bone length (distal bone) then multiplied by 100 to get the eroded bone surface
(Figure4).
RANKL Immunofluorescence Staining
Third-slide specimens were selected for the analysis of RANKL expression in order to confirm
that RANKL had been knocked out from the osteocytes in the DMP1 Cre+.RANKLf/f mice.
Antigen retrieval was undertaken using Proteinase K (1:10 dilution). Nonspecific binding
blocking was performed using donkey serum blocking buffer. The primary antibody was
RANKL Antibody (N-19) (sc-7628) goat polyclonal (Santa Cruz Biotechnology, Santa Cruz,
California) at a concentration of 2 ug (1:100). For control, we used normal goat IgG (5 mg/ml, 15000, Vector) at a concentration of 2 ug (1:100). The specimens were treated with the secondary
antibody of donkey anti-goat biotinylated antibody (1:1000 dilution) (Jackson Immuno Research;
West Grove, Pennsylvania) then subjected to ABC treatment (ABC Vector Elite; Vector Labs)
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and TSA (1:500 dilution). Afterwards, the specimens were subjected to streptavidin-Alexa 546
(invitrogen S1225) (1:400) then mounted in DAPI solution. Measurements were done using MFI
at a maximum intensity of 3000. Six to 7 pictures were taken around the alveolar bone. One
picture was taken of connective tissue right above the bone crest, and another one was taken of
the epithelium. Measurements for the bone (osteocytes), PDL, CT, and epithelium were
determined. All images were captured using a fluorescence microscope (Eclipse 90i; Nikon) and
a Cool-Snap EZ camera. Image analysis was performed using Nikon AR image analysis software
(Nikon).

B-Gal Immunofluorescence Staining
The β-galactosidase (lacZ) gene is a reporter gene that is used to confirm the specificity of other
genes.
Antigen retrieval was performed using citric acid (pH 6.0, 10 mM), and nonspecific binding
blocking was undertaken with donkey serum blocking buffer. The primary antibody was rabbit
anti-beta galactosidase polycolonal antibody (Bioss Antibodies; Woburn, Massachusetts) at a
concentration of 1:200. For control, we used rabbit IgG (1:2500). Secondary antibody treatment
entailed the use of biotinylated donkey anti-rabbit (1:200 conc.) then ABC treatment (ABC
Vector Elite; Vector Labs) followed by streptavidin-Alexa 546 (invitrogen S-11225) (1:400).
The specimens were mounted in DAPI solution. All images were captured using a fluorescence
microscope (Eclipse 90i; Nikon) and a Cool-Snap EZ camera. Image analysis was performed
using Nikon AR image analysis software (Nikon). Since the staining was performed to confirm
tissue specificity, no measurements were obtained.
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Statistical analysis
Statistical analyses were performed using GraphPad Prism6 Software (La Jolla, California). Oneway ANOVA was used to compare the differences between groups; post-hoc tests were used.
The significance level was set at P<0.05, and each group had 5-7 mice.
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Results
Tissue specificity of Dmp1-Cre mice
Beta-galactosidase immunofluorescence of ROSA26 reporter mice revealed the tissue specificity
of DMP1 mice. The test group showed the expression of beta-gal on about 80% of osteocytes
and about 20% of bone lining cells (Figure5). The control group of C57BL/6J mice showed no
expression (Figure5).

Bone area:
Micro CT Analysis
Effect of infection: In the normoglycemic (NG) group, oral infection induced 16% periodontal
bone loss in control (DMP1 Cre−.RANKLf/f) mice compared to the non-infected control
(DMP1 Cre−.RANKLf/f) mice (P<0.05). Infected experimental (DMP1 Cre+.RANKLf/f) mice
showed

no

difference

in

periodontal

bone

loss

from

the

non-infected

control

(DMP1 Cre−.RANKLf/f) mice (P>0.05), (Figure6b).
In the hyperglycemic (HG) group; oral infection induced 22% periodontal bone loss in the
control

(DMP1 Cre−.RANKLf/f)

mice

compared

to

the

non-infected

control

(DMP1 Cre−.RANKLf/f) mice (P<0.05). The infected experimental (DMP1 Cre+.RANKLf/f)
mice showed no difference in periodontal bone loss from the non-infected control
(DMP1 Cre−.RANKLf/f) mice (P>0.05), (Figure7b).
Effect of RANKL: In the normoglycemic (NG) infected group; RANKL deletion played a
significant role. Control (DMP1 Cre−.RANKLf/f) mice had 16% more bone loss than
experimental (DMP1 Cre+.RANKLf/f) mice (P<0.05). In the normoglycemic non-infected group,
RANKL deletion resulted in no significant difference (P>0.05) (Figure6b).
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In the hyperglycemic (HG) infected group, the control (DMP1 Cre−.RANKLf/f) mice had 33%
more bone loss than the experimental (DMP1 Cre+.RANKLf/f) mice (P<0.05). In the
hyperglycemic (HG) non-infected group, the (DMP1 Cre−.RANKLf/f) mice had no significant
bone loss compared to the experimental (DMP1 Cre+.RANKLf/f) mice (P>0.05), (Figure7b).
Effect of diabetes: In the non-infected groups, the hyperglycemic (HG) control
(DMP1 Cre−.RANKLf/f) mice experienced no significant bone loss compared to the
normoglycemic (NG) control (DMP1 Cre−.RANKLf/f) mice (P>0.05). In addition, the
hyperglycemic (HG) experimental (DMP1 Cre+.RANKLf/f) mice experienced no significant
bone loss compared to the normoglycemic (NG) experimental (DMP1 Cre+.RANKLf/f) mice
(P>0.05).
In the infected groups, the hyperglycemic (HG) control (DMP1 Cre−.RANKLf/f) mice
experienced 19% more bone loss than the normoglycemic (NG) control (DMP1 Cre−.RANKLf/f)
mice (P<0.05). The hyperglycemic (HG) experimental (DMP1 Cre+.RANKLf/f) mice
experienced no significant bone loss compared to the normoglycemic (NG) experimental
(DMP1 Cre+.RANKLf/f) mice (P>0.05) (Figure8a).
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Histology Analysis:
A.   Bone area
Effect of infection: In the normoglycemic (NG) group, oral infection induced 19% periodontal
bone loss in the control (DMP1 Cre−.RANKLf/f) mice compared to the group of non-infected
control (DMP1 Cre−.RANKLf/f) mice (P<0.05). Infected experimental (DMP1 Cre+.RANKLf/f)
mice

experienced

no

significant

bone

loss

compared

to

non-infected

control

(DMP1 Cre−.RANKLf/f) mice (P>0.05), (Figure6c).
In the hyperglycemic (HG) group, oral infection induced 31% periodontal bone loss in the
control

(DMP1 Cre−.RANKLf/f)

mice

compared

to

the

non-infected

control

(DMP1 Cre−.RANKLf/f) mice (P<0.05). The infected experimental (DMP1 Cre+.RANKLf/f)
mice experienced no significant bone loss compared to the non-infected control
(DMP1 Cre−.RANKLf/f) mice (P>0.05), (Figure7c).
Effect of RANKL: In the normoglycemic (NG) infected group, RANKL deletion played a
significant role. The control (DMP1 Cre−.RANKLf/f) mice experienced 20% more bone loss
than the experimental (DMP1 Cre+.RANKLf/f) mice (P<0.05), while, in the normoglycemic
(NG) non-infected group, there was no significant difference (P>0.05 (Figure6c).
In the hyperglycemic (HG) infected group, the infected control (DMP1 Cre−.RANKLf/f) mice
experienced 38% more bone loss than the experimental (DMP1 Cre+.RANKLf/f) mice (P<0.05),
while, in the non-infected group, the control (DMP1 Cre−.RANKLf/f) mice experienced no
significant bone loss compared to the experimental (DMP1 Cre+.RANKLf/f) mice (P>0.05),
(Figure7c).
Effect of diabetes: In the non-infected groups, the hyperglycemic (HG) control
(DMP1 Cre−.RANKLf/f) mice experienced no significant bone loss compared to the
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normoglycemic (NG) control (DMP1 Cre−.RANKLf/f) mice (P>0.05). Moreover, the
hyperglycemic (HG) experimental (DMP1 Cre+.RANKLf/f) mice experienced no significant
bone loss compared to normoglycemic (NG) experimental (DMP1 Cre+.RANKLf/f) mice
(P>0.05).
In the infected groups, the hyperglycemic (HG) control (DMP1 Cre−.RANKLf/f) mice
experienced 28% more bone loss than the normoglycemic (NG) control (DMP1 Cre−.RANKLf/f)
mice (P<0.05). In addition, the hyperglycemic (HG) experimental (DMP1 Cre+.RANKLf/f) mice
experienced

no

significant

bone

loss

compared

to

the

normoglycemic

(NG)

(DMP1 Cre+.RANKLf/f) mice, (P>0.05), (Figure8b).

B. Osteoclast counts
Effects of infection:
In the normoglycemic (NG) group, oral infection resulted in 4 times more osteoclasts in the
control (DMP1 Cre−.RANKLf/f) mice than in the non-infected control (DMP1 Cre−.RANKLf/f)
mice (P<0.05). The infected experimental (DMP1 Cre+.RANKLf/f) mice showed no significant
difference from the non-infected control (DMP1 Cre−.RANKLf/f) mice (P>0.05), (Figure6d).
In the hyperglycemic (HG) group, oral infection resulted in 3 times more osteoclasts in the
control (DMP1 Cre−.RANKLf/f) mice than in the non-infected control (DMP1 Cre−.RANKLf/f)
mice (P<0.05). The infected experimental (DMP1 Cre+.RANKLf/f) mice showed no significant
difference from the non-infected control (DMP1 Cre−.RANKLf/f) mice (P>0.05), (Figure7d).
Effect of RANKL:

In the normoglycemic (NG) groups, the infected control

(DMP1 Cre−.RANKLf/f) mice had 5 times more osteoclasts than the infected experimental
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(DMP1 Cre+.RANKLf/f) mice (P<0.05). RANKL deletion had no significant effect on the noninfected normoglycemic (NG) mice (P>0.05), (Figure6d).
In the hyperglycemic (HG) groups, the infected control (DMP1 Cre−.RANKLf/f) mice had 5
times more osteoclasts than the infected experimental (DMP1 Cre+.RANKLf/f) mice (P<0.05).
RANKL deletion had no significant effect on the non-infected normoglycemic (NG) mice
(P>0.05) (Figure7d).
Effect

of

diabetes:

In

the

non-infected

group,

hyperglycemic

(HG)

control

(DMP1 Cre−.RANKLf/f) mice showed no difference in comparison to the normoglycemic (NG)
control (DMP1 Cre−.RANKLf/f) mice (P>0.05). In the infected group, the hyperglycemic (HG)
control (DMP1 Cre−.RANKLf/f) mice had 5 times more osteoclasts than the normoglycemic
(NG) control (DMP1 Cre−.RANKLf/f) mice (P<0.05). Diabetes had no significant effect on the
experimental (DMP1 Cre+.RANKLf/f) mice in the infected and non-infected groups (P>0.05),
(Figure8c).

C. Eroded Bone Surface
Effect

of

infection:

In

the

normoglycemic

(NG)

group,

the

infected

control

(DMP1 Cre−.RANKLf/f) mice had 5.7 times more eroded bone surfaces than the non-infected
control

(DMP1 Cre−.RANKLf/f)

mice

(P<0.05).

The

infected

experimental

(DMP1 Cre+.RANKLf/f) mice showed no difference from the non-infected control
(DMP1 Cre−.RANKLf/f) mice (P>0.05) (Figure6e).
In the hyperglycemic (HG) group, the infected control (DMP1 Cre−.RANKLf/f) mice had 2.7
times more eroded bone surfaces than the non-infected control (DMP1 Cre−.RANKLf/f) mice
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(P<0.05). Furthermore, the infected experimental (DMP1 Cre+.RANKLf/f) mice showed no
difference from the non-infected control (DMP1-Cre−.RANKLf/f) mice (P>0.05) (Figure7e).
Effect

of

RANKL:

In

the

normoglycemic

(NG)

groups,

the

infected

control

(DMP1 Cre−.RANKLf/f) mice had 5.3 times more eroded bone surfaces than the infected
experimental (DMP1 Cre+.RANKLf/f) mice (P<0.05). RANKL deletion had no significant effect
on the non-infected groups (Figure6e).
In the hyperglycemic (HG) groups, the infected control (DMP1 Cre−.RANKLf/f) mice had 3.5
times more eroded bone surfaces than infected experimental (DMP1 Cre+.RANKLf/f) mice,
(P<0.05). RANKL deletion had no significant effect on the non-infected groups (Figure7e).
Effect

of

diabetes:

In

the

non-infected

group,

the

hyperglycemic(HG)

control

(DMP1 Cre−.RANKLf/f) mice showed no difference from the normoglycemic (NG) control
(DMP1 Cre−.RANKLf/f) mice (P>0.05). In the infected group, the hyperglycemic (HG) control
(DMP1 Cre−.RANKLf/f) mice had more eroded bone surfaces than the normoglycemic (NG)
control (DMP1-Cre−.RANKLf/f) mice (P<0.05). In the non-infected group, the hyperglycemic
(HG) control (DMP1 Cre+.RANKLf/f) mice showed no difference from the normoglycemic
(NG)

control

(DMP1 Cre+.RANKLf/f)

mice

(P>0.05).

In

the

infected

group,

the

hyperglycemic(HG) control (DMP1- Cre+.RANKLf/f) mice showed no difference from the
normoglycemic (NG) control (DMP1- Cre+.RANKLf/f) mice (P>0.05), (Figure8d).
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  D. RANKL Immunofluorescence
	
  
Effect of infection: In the normoglycemic (NG) group, oral infection induced 1.5 times more
RANKL expression in the infected control (DMP1 Cre−.RANKLf/f) mice than in the noninfected

control

(DMP1 Cre−.RANKLf/f)

mice

(P<0.05).

The

infected

experimental

(DMP1 Cre+.RANKLf/f) mice showed no difference from the non-infected control
(DMP1 Cre−.RANKLf/f) mice (Figure7f).
In the hyperglycemic (HG) group, oral infection induced 2.2 times more RANKL expression in
the infected control (DMP1 Cre−.RANKLf/f) mice than in the non-infected control
(DMP1 Cre−.RANKLf/f) mice (P<0.05). The infected experimental (DMP1 Cre+.RANKLf/f)
mice showed no difference from the non-infected control (DMP1 Cre−.RANKLf/f) mice
(Figure8f).
Effect of RANKL: In the normoglycemic (NG) groups, the non-infected control
(DMP1 Cre−.RANKLf/f) mice showed no difference from the non-infected experimental
(DMP1 Cre+.RANKLf/f) mice (P>0.05). The infected control (DMP1 Cre−.RANKLf/f) mice
showed

1.6

times

more

RANKL

expression

than

the

infected

experimental

(DMP1 Cre+.RANKLf/f) mice (P<0.05). (Figure7f).
In the hyperglycemic (HG) groups, the non-infected control (DMP1 Cre−.RANKLf/f) mice
showed no difference from the non-infected experimental (DMP1 Cre+.RANKLf/f) mice
(P>0.05). The infected control (DMP1 Cre−.RANKLf/f) mice showed 1.6 times more RANKL
expression than the infected experimental (DMP1 Cre+.RANKLf/f) mice (P<0.05) (Figure8f).
Effect of diabetes: In the non-infected group, the hyperglycemic (HG) control
(DMP1 Cre−.RANKLf/f) mice showed no difference in RANKL expression in the bone from the
normoglycemic (NG) control (DMP1 Cre−.RANKLf/f) mice (P>0.05). In the infected group, the
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hyperglycemic (HG) control (DMP1 Cre−.RANKLf/f) mice showed 1.7 times more RANKL
expression in the bone than the normoglycemic (NG) control (DMP1 Cre−.RANKLf/f) mice
(P<0.05).

In

the

non-infected

group,

the

hyperglycemic

(HG)

experimental

(DMP1 Cre+.RANKLf/f) mice showed no difference in RANKL expression in the bone from the
normoglycemic (NG) experimental (DMP1 Cre+.RANKLf/f) mice (P>0.05). In the infected
group, the hyperglycemic (HG) experimental (DMP1 Cre+.RANKLf/f) mice showed no
difference in RANKL expression in the bone from the normoglycemic (NG) experimental
(DMP1 Cre+.RANKLf/f) mice (P>0.05) (Figure8e).
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Discussion
We confirmed the tissue specificity of DMP1 in osteocytes. About 80% of periodontal bone
osteocytes in the (DMP1-Cre.ROSA26) mice (about 20% of the bone lining cells) showed DMP1
expression. These lining cells could be osteocytes that have started to form on the bone’s surface
(Dallas et al. 2013; Dallas et al. 2015) or osteoblasts that form bone lining cells (Xiong et al.
2015).
Toyosawa et al. (2001) showed that DMP1 is expressed in the osteocytes of chicken and rat tibia.
Feng et al. (2002) demonstrated DMP1 expression in the osteocytes of mice. RANKL expression
in osteocytes was first identified in vitro from chick cells (Tanaka et al. 1995) and later identified
in MLO-Y4 osteocyte-like cells (from mice) (Zhao et al. 2002).
The oral inoculation model of Porphyromonas gingivalis–Fusobacterium nucleatum bacteria
(Pg-Fn) has shown their ability to induce periodontal bone loss. This is consistent with the
findings of (Polak et al. 2009). These bacteria produce several pathogenic factors that induce
tissue destruction as well as propagate the host response to inflammation. Periodontal tissue
destructions occur as a result of bacterial infection and host response. Several cellular events
happen during infection with these bacteria, including innate and adaptive immune response.
RANKL plays a major role in the differentiation and activation of osteoclasts. Activated
osteoclasts resorb the bone. The role of RANKL from the osteocytes in the regulation of
physiological bone remodeling has been well established (Nakashima et al. 2011; O’Brien and
Xiong 2012; Xiong et al. 2015). However, the role of osteocytes in inflammation-induced bone
loss is not well understood.
Periodontal bone loss was observed in infected control (DMP1-Cre−.RANKLf/f) mice as evident
from the remaining bone area in the results of both microCT and histology. This bone loss
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resulted from increased osteoclast activity, which was proven through the significantly increased
number of osteoclasts in the infected control (DMP1-Cre−.RANKLf/f) mice. The same pattern
was observed for the eroded bone surface and RANKL expression. On the other hand, there was
lack of periodontal bone loss in infected experimental (DMP1-Cre+.RANKLf/f) mice.
Although RANKL is described as a membrane-bound protein (Anderson et al. 1997), Lum et al.
(1999) showed that it can also be expressed in soluble form. Nakashima et al. (2011) suggested
that the membrane-bound form of RANKL is more potent. Osteocytes have dendritic processes
that connect them to each other. These dendritic processes can reach the bone surface and come
into direct contact with osteoblasts and osteoclasts (Dallas et al. 2015). Through these possible
pathways, osteocytes play a major role in controlling bone remodeling.
In this study, we found that diabetes enhances periodontal bone loss, which is consistent with
earlier studies (Graves et al. 2006; Pacios et al. 2012). Diabetes can enhance inflammatory bone
loss through the upregulation of the inflammatory response and the downregulation of the
healing response. The findings in hyperglycemic (HG) infected control (DMP1-Cre−.RANKLf/f)
mice were as expected: more osteoclasts and RANKL expression as results of higher
inflammatory response to the periodontal infection as well as of the impaired reparative capacity.
However, the new finding in this study is the prevention of periodontal bone loss through the
blocking of RANKL from osteocytes.
It was thought that RANKL-induced periodontal bone loss is mainly from lymphocytes (Kawai
et al. 2006). Recent findings from Pacios et al. (2015) revealed the important role of osteoblast
lineage cells in RANKL-induced periodontal bone loss. This study revealed the critical role of
osteocytes in inflammation-induced periodontal bone loss. However, further investigations are
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needed, such as measuring the mRNA expression of RANKL and investigating the transcription
level of the cellular mechanism of osteocytes in inflammatory bone loss.
The findings of this study open doors for new possible areas to study the role of other cells in
controlling inflammatory bone loss. One of these is periodontal ligament fibroblast.
Based on our results we reject both of the null hypothesis and we accept both of the alternative
hypothesis. We demonstrated for the first time the important role of osteocytes in periodontal
bone loss through the expression of RANKL. This finding may contribute to future studies that
target cells of this type, thus preventing inflammatory bone loss.
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Annexes

RANKL	
  
	
  
	
  
	
  
	
  
	
  
	
  
Cre	
  

Figure1: PCR to confirm genotyping of RANKL and Cre.

Figure2, A: measurement box at the level of the CEJs of the first and
second molars, B: Total area and bone area measured between the
distal and mesial roots of the first and second molars respectively.

	
  

	
  

41	
  

Figure3: Bone area measurements.

Figure4: Trap staining for osteoclasts and eroded bone.
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Figure5: Expression of DMP1 in (DMP1-Cre.ROSA26) mice and in control (C57BL/6J) mice.
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Figure 6. RANKL deletion from osteocyte block periodontitis-induced periodontal bone loss in
normoglycemic mice. P. gingivalis and F. nucleatum, or vehicle alone, were orally inoculated into control
(DMP1 Cre−.RANKLf/f) mice (Cre-) and experimental (DMP1-Cre+.RANKLf/f) mice (Cre+). The mice were
euthanized 6 weeks after oral inoculation. (a) Hematoxylin and eosin (HE) stained mice periodontal tissues in
a longitudinal plan (original magnification 200x). Solid line marks the interproximal bone area (between the
first and the second maxillary molar) in sections from normoglycemic (NG) noninfected or infected control
(Cre-) mice and infected experimental (Cre+) mice. (b) MiroCT analysis of the bone area between the first and
the second maxillary molar. (c) HE histology analysis of the bone area between the first and the second
maxillary molar. (d, e) Osteoclasts were counted as multinucleated cells lining the bone surface in sections
stained by tartrate-resistant acid phosphatase (TRAP). Eroded bone surface was measured as the length of
resorption lacunae divided by the total bone length in TRAP-stained sections. (f, g) The RANKL expression
from osteocytes were analyzed using the quantification of the mean fluorescence intensity (MFI) of the
immunofluorescence images of the interproximal bone. Cells were stained with RANKL (red) and
counterstained with DAPI (blue). For each group, n = 5–7. Data represent the mean + SEM. ✻ Significantly
different in the infected compared with the matched noninfected group; ✛ significantly different in the
infected experimental compared with the infected control. P < 0.05.
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Figure 7. RANKL deletion from osteocyte block periodontitis-induced periodontal bone loss in
hyperglycemic mice. P. gingivalis and F. nucleatum, or their vehicle alone, were orally inoculated into
diabetic control (DMP1 Cre−.RANKLf/f) mice (Cre-) and experimental (DMP1-Cre+.RANKLf/f) mice (Cre+).
The mice were euthanized 6 weeks after oral inoculation. (a) Hematoxylin and eosin (HE) stained mice
periodontal tissues in a longitudinal plan (original magnification 200x). Solid line marks the interproximal
bone area (between the first and the second maxillary molar) in sections from hyperglycemic (HG) noninfected
or infected control (Cre-) mice and infected experimental (Cre+) mice. (b) MiroCT analysis of the bone area
between the first and the second maxillary molar. (c) HE histology analysis of the bone area between the first
and the second maxillary molar. (d, e) Osteoclasts were counted as multinucleated cells lining the bone surface
in sections stained by tartrate-resistant acid phosphatase (TRAP). Eroded bone surface was measured as the
length of resorption lacunae divided by the total bone length in TRAP-stained sections. (f, g) The RANKL
expression from osteocytes were analyzed using the quantification of the mean fluorescence intensity (MFI) of
the immunofluorescence images of the interproximal bone. Cells were stained with RANKL (red) and
counterstained with DAPI (blue). For each group, n = 5–7. Data represent the mean + SEM. ✻ Significantly
different in the infected compared with the matched noninfected group; ✛ significantly different in the
infected experimental compared with the infected control. P < 0.05.
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Figure 8. Diabetes-enhanced periodontitis-induced periodontal bone loss. The combined results of both the
normoglycemic (NG) and the hyperglycemic (HG) group. (a) MiroCT analysis. (b) HE histology analysis. (c,
d) Osteoclast counts. Eroded bone in TRAP-stained sections. (e) RANKL expression from osteocytes. For
each group, n = 5–7. Data represent the mean + SEM. ✻ Significantly different in the normoglycemic(NG)
compared with the matched hyperglycemic (HG) group. P < 0.05.
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